WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that it received the requisite number of written consents to add all three of its director candidates – Robert Postma, Jaime Vieser and Holger Weis – to the Company’s Board of Directors (the “Board”). Although each member of WaterMill’s slate received support from holders of more than 50% of Ziopharm’s outstanding shares, only Messrs. Vieser and Weis are able to join as directors due to the Company’s Board currently being capped at eight members. WaterMill also received the requisite number of consents to remove Scott Tariff from the Board.